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Abstract
Following an application from Tate & Lyle PLC submitted for authorisation of a health claim pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to polydextrose and maintenance of normal
defecation. The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence. The food constituent that is the subject of the health claim is
‘polydextrose’. The Panel considers that polydextrose is sufﬁciently characterised. The claimed effect
proposed by the applicant is ‘improved bowel function by increasing stool bulk’. The target population
proposed by the applicant is ‘the general population’. The Panel considers that maintenance of normal
defecation is a beneﬁcial physiological effect. In weighing the evidence, the Panel took into account
that, out of the three human intervention studies from which conclusions could be drawn for the
scientiﬁc substantiation of the claim, one study showed an effect at doses of 20 g/day when
polydextrose was given for 10 days, whereas two studies in which polydextrose was administered at
doses of 21 and 18 g/day for longer periods of time did not show an effect. The Panel also took into
account that the evidence provided for the mechanisms by which polydextrose could contribute to the
maintenance of normal defecation in vivo in humans is weak. The Panel concludes that a cause and
effect relationship has not been established between the consumption of polydextrose and
maintenance of normal defecation.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following an application from Tate & Lyle PLC submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United
Kingdom, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and
Allergies (NDA) was asked to deliver an opinion on the scientiﬁc substantiation of a health claim
related to polydextrose and maintenance of normal defecation.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence. The application included a request for the protection of proprietary data.
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on the evaluation of Article 13.5 and 14 health claims and
the guidance on the scientiﬁc requirements for health claims related to the immune system, the
gastrointestinal tract and defence against pathogenic microorganisms.
The food constituent that is the subject of the health claim is ‘polydextrose’. The Panel considers
that polydextrose is sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘improved bowel function by increasing stool bulk’.
The target population proposed by the applicant is ‘the general population’. The Panel considers that
maintenance of normal defecation is a beneﬁcial physiological effect.
A claim submitted under the Article 13(1) procedure on polydextrose and changes in bowel function
was evaluated by the Panel with an unfavourable opinion on the basis of the poor methodological
quality of the human intervention studies which were submitted for substantiation. In addition to
these, the applicant has provided three other human intervention studies which have investigated the
effects of polydextrose on different outcome variables related to the claimed effect and three in vitro
studies as being pertinent to the claim.
In weighing the evidence, the Panel took into account that, out of the three human intervention
studies from which conclusions could be drawn for the scientiﬁc substantiation of the claim, one study
showed an effect at doses of 20 g/day when polydextrose was given for 10 days, whereas two studies
in which polydextrose was administered at doses of 21 and 18 g/day for longer periods of time
(3–4 weeks) did not show an effect of the intervention on the maintenance of normal defecation. The
Panel also took into account that the evidence provided for the mechanisms by which polydextrose
could contribute to the maintenance of normal defecation in vivo in humans under the proposed
conditions of use is weak.
On the basis of data presented, the Panel concludes that a cause and effect relationship has not
been established between the consumption of polydextrose and maintenance of normal defecation.
Polydextrose and normal defecation
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
in disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of the Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: polydextrose and maintenance of
normal defecation.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of polydextrose, a positive assessment of its safety, nor a decision on whether polydextrose
is, or is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
1.3. Additional information
A claim on polydextrose and changes in bowel function has already been assessed by the
Panel with unfavourable outcome (EFSA NDA Panel, 2011a).
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
2.1.1.1. Food constituent as stated by the applicant
According to the applicant, the food constituent that is the subject of the claim is polydextrose.
Polydextrose is a randomly bonded, water-soluble, low-calorie non-starch polysaccharide, used
primarily as a bulking agent and texturiser in foods. It is a highly branched dextrose polymer and has
a broad molecular weight (mw) range (162–20,000) with 90% of the molecules being between 504
and 5,000 mw. Polydextrose is non-sweet, and has been used as a low-calorie bulking agent and
soluble ﬁbre ingredient in many food products worldwide for over 25 years. In most countries,
polydextrose is usually declared as a dietary ﬁbre.
2.1.1.2. Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to the improvement of bowel function by
increasing faecal bulk.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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2.1.1.3. Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘Polydextrose contributes to
an improved bowel function by increasing stool bulk’.
2.1.1.4. Speciﬁc conditions of use as proposed by the applicant
According to the applicant, the claimed effect is based on a daily ingestion of 18 g polydextrose,
which can be consumed over several portions per day. Appropriate conditions reﬂecting the overall
science would include foods that carry the nutrition claim ‘high in ﬁbre’ or wording reﬂecting the same
meaning, which would be in line with similar approved claims. The target population proposed by the
applicant is the general population.
2.1.2. Data provided by the applicant
The applicant provided a health claim application on polydextrose and maintenance of normal
defecation pursuant to Article 13.5 of Regulation 1924/2006. The application was presented in a
common and structured format as outlined in the Scientiﬁc and technical guidance for the preparation
and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011b).
As outlined in the EFSA General guidance for stakeholders on the evaluation of Article 13.1, 13.5
and 14 health claims (EFSA NDA Panel, 2016a), it is the responsibility of the applicant to provide the
totality of the available evidence.
2.2. Methodologies
The general approach of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) for the
evaluation of health claims applications is outlined in the EFSA general guidance for stakeholders on
health claim applications (EFSA NDA Panel, 2016a).
The scientiﬁc requirements for health claims related to the immune system, the gastrointestinal
(GI) tract and defence against pathogenic microorganisms are outlined in a speciﬁc EFSA guidance
(EFSA NDA Panel 2016b).
3. Assessment
3.1. Characterisation of the food constituent
The food constituent which is the subject of the health claim is polydextrose.
Polydextrose is produced by the polycondensation of glucose in the presence of sorbitol and citric
acid under vacuum at high temperatures (Radosta et al., 1992). Polydextrose is highly branched, with a
degree of polymerisation between 2 and 110 (on average approximately 12 glucose units), and with an
average mw of ~ 2,000 Da (Allingham, 1982; Murray, 1988). All possible linkages with the glycosidic
carbon of glucose are present: a- and b-1,2; 1,3; 1,4; and 1,6; with the 1,6 linkage predominating
(Auerbach et al., 2007). Polydextrose is highly soluble in water (80 g/100 g at 25°C), leading to a low
viscosity solution (Allingham, 1982; Auerbach et al., 2007). Besides the polymer, polydextrose consists
of small amounts of the starting materials glucose, sorbitol and citric acid, as well as levoglucosan and
hydroxymethylfurfural, formed by caramelisation during the polycondensation process. Polydextrose is
used primarily in the food industry as a stabiliser, thickening agent, humectant and carrier (E 1200).
Polydextrose is available in granular (ﬁne or regular) and liquid forms. Upon a request from EFSA,
the applicant speciﬁed that the content of sugars (mono- and disaccharides) in 100 g of the product is
3.2 g. Information about the manufacturing process, stability and variability between batches was
provided in the application. Polydextrose can be measured in foods by established methods.
The Panel considers that polydextrose is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘improved bowel function by increasing stool bulk’.
The target population proposed by the applicant is ‘the general population’.
EFSA informed the applicant that, in the context of the information provided in the application and
of the human studies submitted for substantiation of the claim, the proposed claimed effect refers to
the maintenance of normal defecation (in the context of constipation), as outlined in the updated
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guidance on the scientiﬁc requirements for health claims related to gut and immune function (EFSA
NDA Panel, 2016b).
The maintenance of normal defecation may be assessed by a number of outcome variables which
could provide information about the function and eventually about the underlying mechanism of
action, some of which may be interrelated (e.g. frequency of defecations, stool consistency, sensation
of complete/incomplete evacuation, faecal bulk, transit time). Although reduced stool frequency and
consistency are among the signs/symptoms of functional constipation, changes in transit time and
faecal bulk may or may not contribute to the maintenance of normal defecation in the context of
constipation.
The Panel considers that the maintenance of normal defecation is a beneﬁcial physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in PubMed, Centre for Agriculture and Biosciences
(CAB) abstracts, Sci Finder and Science Direct databases with the use of the following key words:
polydextrose AND (gut OR intestine OR bowel OR feces OR faecal bulk OR faeces OR transit) AND
(human* OR adult*) NOT (baby OR babies OR child* OR infant* OR toddler*). Papers written in
English or French were included.
A claim submitted under the Article 13(1) procedure on polydextrose and changes in bowel function
was evaluated by the Panel with an unfavourable opinion on the basis of the poor methodological
quality of the human intervention studies which were submitted for substantiation (Tomlin and Read,
1988; Endo et al., 1991; Achour et al., 1994; Jie et al., 2000). In addition to these, the applicant has
provided three other human intervention studies which have investigated the effects of polydextrose
on different outcome variables related to the claimed effect (Timm et al., 2013; Vester Boler et al.,
2011; Sarkkinen et al., 2014) and three in vitro studies as being pertinent to the claim.
3.3.1. Human efﬁcacy studies
Vester Boler et al. (2011) compared the effect of snacks containing either polydextrose (21 g/day),
soluble corn ﬁbre (21 g/day) or no ﬁbre (control) on several GI outcomes in 25 young healthy men
(mean age 27.5  4.3 years). The study was designed as a randomised, double-blind, placebo-
controlled, crossover study consisting of three consecutive periods lasting 21 days (no wash-out). The
study foods were snack bars made of rice crisps, each containing approximately 7 g of either
polydextrose or soluble corn ﬁbre or no ﬁbre (control). The participants were asked to consume three
bars daily. The three crossover intervention periods were assigned in a randomised order. Faeces were
collected during the last 5 days of each study period. The outcomes measured included wet and dry
stool weight, defecation frequency, stool consistency and ease of stool passage, among others (e.g.
faecal composition and chemistry, symptoms of GI discomfort). A total of 21 subjects completed the
study and entered data analysis (three did not initiate the study for reasons unrelated to the study
and one was removed by the investigators based on predeﬁned stopping rules). Data were analysed
using the mixed models procedure of SAS. The ﬁxed effect of treatment was tested considering period
and subject as random effects. Total dietary ﬁbre was used as a covariate. Differences among
treatments were determined using a Fisher-protected least signiﬁcant difference with a Tukey
adjustment.
The macronutrient composition of the background diet did not differ signiﬁcantly between periods.
Mean daily ﬁbre intake (excluding the supplemental ﬁbres) was between 14.4 and 14.8 g/day and was
not signiﬁcantly different between periods. Faecal dry weight was signiﬁcantly higher during the
polydextrose period than during the placebo period (184.8 vs 155.9 g, pooled standard error of the
mean (SEM) = 11.81, p = 0.02), while no signiﬁcant differences between the polydextrose and placebo
periods were reported for wet stool weight, frequency of defecations, stool consistency or subjective
feeling of ease of stool passage. The Panel considers that this study does not show an effect of
polydextrose on the maintenance of normal defecation when consumed at doses of 21 g/day for
3 weeks.
In a randomised, double-blind, placebo-controlled, crossover study of similar design, Timm et al.
(2013) investigated the effects of polydextrose (20 g/day), soluble corn ﬁbre (20 g/day) and low-ﬁbre
control (no added ﬁbre) on several GI outcomes. The study consisted of three intervention periods
lasting 10 days each, with 2-week wash-out periods in between. Participants (n = 36, 18 females,
mean age 25.8  9.1 years) were screened to be on low-ﬁbre (< 15 g/day) background diets and
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were asked to maintain such diets throughout the study. In addition, they were instructed to consume
one packet of cereal and one mufﬁn (with either polydextrose, soluble corn ﬁbre or no added ﬁbre)
each day during the study periods. The three crossover intervention periods were assigned in a
randomised order. Food records were collected for 3 days during each period. Participants recorded
the time and date of each defecation and evaluated stool consistency using the Bristol stool scale. On
day 6 of each period, participants swallowed 20 radio-opaque marker (ROM) pellets and collected their
faeces for the ﬁve remaining days. They also kept a 5-day bowel movement diary where time and date
of each movement were recorded, and collected all faecal samples. Whole gut transit time (WGTT)
was investigated by X-raying each faecal sample to observe the passage of the ROM pellets. The 80%
transit time method was used to calculate WGTT. GI comfort was assessed using a self-reported
questionnaire. All participants completed the study and entered data analysis. Treatments were
compared using mixed-effects linear models with treatment and visit as ﬁxed effects and with a
random intercept for each participant to model correlation between repeated measurements from the
same participant. For each outcome, equal carry-over and treatment–visit interaction were checked by
the mixed-effects models. Differences of least square means were used to determine differences
among treatments.
During the polydextrose period, the frequency of defecations and wet stool weight were
signiﬁcantly higher compared to the low-ﬁbre control period (5.5  2.3 vs 4.4  2.1/5 days,
p = 0.0005; and 830  443 g vs 623  342 g, p = 0.0007, respectively). The consistency of stools
during the polydextrose period was also softer compared to the control period (4.67 vs 3.86,
p = 0.002). WGTT did not differ signiﬁcantly between periods. The Panel notes the short duration of
the intervention (10 days). The study products were well tolerated and no differences among the
treatment periods for the bowel habit quality-of-life question were observed. The Panel considers that
this short-term study shows an effect of polydextrose on the maintenance of normal defecation when
consumed at doses of 20 g/day for 10 days.
In a randomised, double-blind, placebo-controlled, crossover study, Sarkkinen et al. (2014,
unpublished, claimed as proprietary by the applicant) investigated the effect of polydextrose
(18 g/day) compared to placebo (no polydextrose) in mildly constipated subjects (3–5 defecations/
week). The study was divided into four periods: a 2-week run-in period, two 4-week intervention
periods and a 6- to 8-week wash-out period between the intervention periods. During the
intervention periods, subjects consumed two sachets of a drink mixture and three biscuits (one
portion) daily providing 18 g of polydextrose or the same products containing no polydextrose. The
two crossover intervention periods were assigned in a randomised order. Treatment compliance was
set to > 80% product consumption. Faeces were collected by subjects at home, during four
consecutive days, starting not earlier than the 21st day and not later than the 24th day of each
intervention period, and before the measurement of total colonic transit time (CTT), which started
the last day of faeces collection. CTT was measured using a ROM technique. Participants ingested
two capsules (10 pellets each) at 24-h intervals for three consecutive days. One simple abdominal
radiograph (one projection) was taken at the supine position 24 h after the ingestion of the last
pellets. Stool consistency was assessed by subjects using the Bristol Stool Form scale during seven
consecutive days at the run-in period, both interventions and the wash-out period. Participants also
assessed the ease of stool passage at the end of the each intervention period. The primary outcome
of the study was faecal wet weight, the variable which was used for sample size calculations. A
sample size of 50 subjects was planned in order to be able to detect a difference of 20 g in mean
daily stool bulk between the treatment periods with a probability of 80% at a level of 0.05. A total
of 73 subjects were randomised to ensure that at least 50 subjects would have completed the study.
Secondary outcomes included frequency of bowel movements, stool consistency, CTT and subjective
scoring of GI tolerance. Intention-to-treat (ITT) analysis included all randomised subjects completing
the study and the PP analysis included all randomised subjects completing the study as planned (i.e.
without signiﬁcantly violating the inclusion/exclusion criteria or other aspects of the protocol
considered to potentially affect the study efﬁcacy). The Panel notes that analysis of completers
rather than an actual ITT was applied. The general linear model for the repeated measures was
used in the crossover analyses of the primary outcome. As a signiﬁcant (and unexplained) carry-over
effect was found when analysing the primary outcome, the results of the second treatment period
were no longer considered. Data from the ﬁrst period was analysed as a randomised double-blind
placebo-controlled parallel study. Differences between the study groups were analysed using the
Student’s t-test and the Wilcoxon rank sum test. It was estimated that for a sample size of 26
subjects per group (completers) and using an estimated standard deviation of 50 g for the stool
Polydextrose and normal defecation
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2016;14(5):4480
bulk, the study would be able to detect a difference of 38.5 g in mean daily stool bulk between the
study groups with a probability of 80% at a-level of 0.05.
Ten subjects dropped out of the study and another 10 subjects were withdrawn from the study.
One subject was excluded from the completers analysis (n = 52; 26 in the polydextrose and placebo
groups) for suspected GI illness during the study. Another subject not consuming the study products
as planned was excluded from the PP analyses (n = 51; 25 in the placebo group).
Mean faecal wet weight (g/4 days) was signiﬁcantly higher in the polydextrose than in the placebo
group (mean  SD: 406.7  210.1 vs 286.0  167.0 g, p = 0.047, Wilcoxon). Mean faecal dry weight
(g/4 days) was also signiﬁcantly higher in the polydextrose group (mean  SD: 110.4  47.1 vs
84.7  46.4 g, p = 0.045, Wilcoxon). In completers, only wet faecal weigh was signiﬁcantly higher in
the polydextrose group (406.7  210.1 vs 296.7  172.5 g) and only using a t-test for the analysis
(p = 0.044) but not when using the Wilcoxon test (p = 0.075). Frequency of defecations, stool
consistency, self-reported ease of stool passage and CTT were not statistically different between the
groups in the PP or completers analyses. The Panel considers that this study does not show an effect
of polydextrose when consumed at doses of 18 g/day for 28 days on the maintenance of normal
defecation.
The Panel notes that three human intervention studies were performed both in healthy and
constipated populations, using similar daily dose of polydextrose (from 18 to 21 g), with the sample
size from 21 to 36 subjects and with the mean age of participants from 25 to 48 years. The
Panel notes that two of these studies, with the intervention period of 21 and 28 days, did not show an
effect of polydextrose on the maintenance of normal defecation (Vester Boler et al., 2011; Sarkkinen
et al., 2014), while the third, short-term study with the intervention period lasting 10 days, showed an
effect of polydextrose on maintenance of normal defecation (Timm et al., 2013).
In the previous opinion on polydextrose and changes in bowel function (EFSA NDA Panel, 2011a),
the Panel evaluated four human intervention studies, which, in isolation, could not be used for the
scientiﬁc substantiation of the claim owing to their methodological limitations. The Panel, however, will
consider whether these studies could support an effect of polydextrose on the maintenance of normal
defecation in the light of the additional evidence provided by the applicant.
Endo et al. (1991), in a single-arm, sequential, non-randomised intervention study, evaluated faecal
weight in eight healthy volunteers (six male) given a low-cholesterol diet, a high-cholesterol diet and a
high-cholesterol diet supplemented with polydextrose (15 g/day) for two consecutive weeks each.
Other outcome variables related to the maintenance of normal defecation were not assessed. The
Panel considers that no conclusions can be drawn from this study for the scientiﬁc substantiation of
the claim.
In a single-arm, sequential study in seven male volunteers on a controlled diet, (Achour et al.,
1994) subjects consumed no polydextrose and a controlled diet for the ﬁrst 8 days, 30 g/day of
polydextrose and a controlled diet from days 9 to 16, and 30 g/day of polydextrose eating ad libitum
from days 17 to 38. The Panel considers that no conclusions can be drawn from this study for the
scientiﬁc substantiation of the claim.
Tomlin and Read (1988) investigated the effect of polydextrose consumed in addition to the usual
diet on WGTT, stool mass, stool frequency and stool consistency in a group of 12 healthy male
volunteers in a randomised, single-blind, three-arm, crossover study. After a 10-day run-in period,
subjects received 30 g/day of polydextrose, 7 g/day of psyllium, and a mixture of polydextrose and
psyllium (30 and 2 g/day, respectively) for 10 days each with a one-week wash-out period in between.
The statistical signiﬁcance of differences between the three intervention periods and the run-in period
was tested by the Wilcoxon’s matched-pairs signed ranks test. The Panel notes that the statistical
analysis is not appropriate for the study design. The Panel considers that no conclusions can be drawn
from this study for the scientiﬁc substantiation of the claim.
In a randomised, placebo-controlled, double-blind, four-arm, parallel study, the effect of
polydextrose (0, 4, 8 or 12 g/day given for 28 days) added to the usual diet on the frequency of
defecation and on faecal wet and dry weight was investigated in 120 healthy volunteers (66 men; 30
subjects per group) (Jie et al., 2000). Analysis of variance (ANOVA) and the Dunnett’s multiple
(pair-wise) comparisons procedure was used to assess differences between the polydextrose groups
and placebo. The Panel notes that the overall effect (with the use of ANOVA) was not reported in the
paper, that comparisons were not made among the different polydextrose groups and that no formal
dose–response analysis was presented, despite the study design. The Panel considers that no
conclusions can be drawn from this study for the scientiﬁc substantiation of the claim.
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The Panel notes that, out of the three human intervention studies from which conclusions could be
drawn for the scientiﬁc substantiation of the claim, one study showed an effect at doses of 20 g/day
when polydextrose was given for 10 days (Timm et al., 2013), whereas two studies in which
polydextrose was administered at doses of 21 (Vester Boler et al., 2011) and 18 g/day (Sarkkinen
et al., 2014, unpublished, claimed as proprietary) for longer periods of time (3–4 weeks) did not show
an effect of the intervention on the maintenance of normal defecation.
3.3.2. Mechanism by which the food constituent could exert the claimed effect
According to the applicant, polydextrose exerts the claimed effect by reaching the colon
undigested, where it is slowly and only partially fermented by the colonic bacteria. About half of the
polydextrose ingested would be excreted intact with the faeces, which would contribute to increased
faecal mass per se and exert a mild osmotic effect. Colonic fermentation of polydextrose would, in
addition, increase bacterial mass and the production of short-chain fatty acids (SCFA), which may
promote peristalsis and increase faecal bulk.
Three in vitro studies provided by the applicant show partial fermentation of polydextrose in
artiﬁcial models of the human colon, as well as an increased production of SCFA (Solomons and
Rosenthal, 1985; Arrigoni et al., 1999; M€akivuokko et al., 2005). A metabolic study in humans using
labelled polydextrose also showed that about 50% of the ingested polydextrose is fermented in the
colon (Figdor and Bianchine, 1983).
However, the Panel notes that in the human intervention studies provided by the applicant for
the scientiﬁc substantiation of this claim, no effect of polydextrose on the composition of the gut
microbiota (with the exception of decreasing number of Clostridium perfringens) (Endo et al., 1991),
or a change in the bacterial proﬁle with increased production of SCFA (Jie et al., 2000) were
reported. In addition, consumption of 30 g/day of polydextrose did not signiﬁcantly affect the
bacterial mass (calculated as % faecal dry matter) in the only study which assessed this outcome
(Achour et al., 1994), and which also showed no effect of polydextrose on wet or dry faecal weight.
The Panel also notes that, in the human studies provided, polydextrose does not appear to affect
transit time signiﬁcantly, and that its effects on dry and wet faecal weight are inconsistent across
studies: one study reported an increase in dry (but not wet) faecal weight at doses of 21 g/day
(Vester Boler et al., 2011); one study reported an increase in wet faecal weight at doses of 20 g/day
and did not report on dry faecal weight (Timm et al., 2013); one study showed no consistent effect
on either dry or wet faecal weight at doses of 18 g/day (Sarkkinen et al., 2014; unpublished,
claimed as proprietary); and two studies reported signiﬁcant effects on faecal mass at 30 g/day
(Tomlin and Read, 1988) and on dry and wet faecal weight at doses as low as 4 g/day (Jie et al.,
2000).
The Panel considers that the experimental studies submitted by the applicant provide some
evidence that polydextrose is partially fermented in the colon, increasing SCFA production. However, in
human studies no evidence has been provided for an effect of polydextrose on bacterial mass, and the
evidence provided for the bulking capacity of polydextrose through an osmotic effect is inconsistent.
Therefore, the Panel considers that the evidence provided for the mechanisms by which polydextrose
could contribute to the maintenance of normal defecation in vivo in humans under the proposed
conditions of use is weak.
3.3.3. Weighing of the evidence
In weighing the evidence, the Panel took into account that, out of the three human intervention
studies from which conclusions could be drawn for the scientiﬁc substantiation of the claim, one study
showed an effect at doses of 20 g/day when polydextrose was given for 10 days, whereas two studies
in which polydextrose was administered at doses of 21 and 18 g/day for longer periods of time
(3–4 weeks) did not show an effect of the intervention on the maintenance of normal defecation. The
Panel also took into account that the evidence provided for the mechanisms by which polydextrose
could contribute to the maintenance of normal defecation in vivo in humans under the proposed
conditions of use is weak.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of polydextrose and maintenance of normal defecation.
Polydextrose and normal defecation
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2016;14(5):4480
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food constituent, polydextrose, which is the subject of the health claim, is sufﬁciently
characterised.
• The claimed effect proposed by the applicant is ‘improved bowel function by increasing stool
bulk’. The target population proposed by the applicant is general population. Maintenance of
normal defecation is a beneﬁcial physiological effect.
• A cause and effect relationship has not been established between the consumption of
polydextrose and maintenance of normal defecation.
Documentation provided to EFSA
Health claim application on polydextrose and maintain normal defecation pursuant to Article 13(5)
of Regulation (EC) No 1924/2006 (Claim serial No: 0440_UK). Submitted by Tate & Lyle PLC, 1
Kingsway, London WC2B 6AT, United Kingdom.
1) This application was received by EFSA on 28/9/2015.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence. The application included a request for the protection of
proprietary data.
3) The scientiﬁc evaluation procedure started on 12/11/2015.
4) On 24/11/2015, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 3/12/2015 and was restarted on 18/12/2015, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
5) On 22/12/2015, EFSA received the applicant’s reply.
6) On 19/1/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 28/1/2016 and was restarted on 2/2/2016, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
7) On 2/2/2016, EFSA received the applicant’s reply.
8) During its meeting on 20/4/2016, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to polydextrose and
maintenance of normal defecation.
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Abbreviations
ANOVA analysis of variance
CAB Centre for Agriculture and Biosciences
CTT colonic transit time
GI gastrointestinal
ITT intention-to-treat
mw molecular weight
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
PP per protocol
ROM radio-opaque marker
SCFA short- chain fatty acids
SEM standard error of the mean
WGTT whole gut transit time
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